Northwest Biotherapeutics intends to price public sale of equity units

Deal sells units through Oppenheimer to fund research and development

By Devika Patel

Knoxville, Tenn., Nov. 19 - Northwest Biotherapeutics, Inc. plans to price a public offering of units, according to a preliminary prospectus supplement filed Tuesday with the Securities and Exchange Commission.

The units will consist of one common share and warrants to purchase common shares.

Oppenheimer & Co. is the bookrunning manager.

Proceeds will be used for research and development activities, working capital and other general corporate purposes.

Northwest Biotherapeutics is a development-stage biotechnology company based in Bothell, Wash., with a focus on cancer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.